Market Overview:
The global HER2-positive breast cancer market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of HER2-positive breast cancer, technological advancements in the field of oncology, and rising awareness about HER2-positive breast cancer. Based on type, the global HER2-positive breast cancer market is segmented into grifola frondosa, surgery, radiation and chemotherapy, endocrine therapy, molecular targeted therapy, and other therapies. Grifola frondosa accounted for the largest share of the global HER2-positive breast cancer market in 2017 owing to its ability to inhibit tumor growth and metastasis. Based on application, the hospital segment accounted for the largest share of the global HER2-positive breast cancer market in 2017 owing to increased use of targeted therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) in hospitals.
Product Definition:
HER2-positive breast cancer is a type of breast cancer that test positive for the HER2 protein. The presence of the HER2 protein indicates that the tumor is likely to grow and spread more quickly than other types of breast cancer.
Grifola Frondosa:
Grifola frondosa, also known as the Asian or Chinese mushroom, is a medicinal fungus belonging to the family of Ganodermataceae. It is primarily used in traditional Chinese medicine for its ability to enhance blood flow and reduce blood clotting.
Surgery:
Surgery is a medical procedure used to remove abnormal tissues or organs. The main goal of surgery is to cure, repair, or improve a particular body function or structure. Surgery can be performed on all types of patients ranging from infants to the geriatric population with various diseases and disorders. Some examples are hernia repair surgery, heart valve replacement surgery (aortic and mitral), bariatric surgeries for weight loss management, etc.
Application Insights:
On the basis of application, the global market is segmented into hospital, specialty clinic, biotechnology and pharmaceutical companies, research and academic institutions. Hospital held the largest share in 2017 due to presence of a large number of hospitals that offer advanced treatment for cancer patients. In addition, increasing R&D activities by major players such as Pfizer and Merck for developing new drugs to treat breast cancer is expected to boost revenue generation over the forecast period.
Specialty clinics are anticipated to witness lucrative growth owing to rising awareness about personalized medicine among individuals suffering from various types of cancers including HER2-positive breast cancer. Moreover, increasing adoption of molecularly targeted therapies is further expected to drive demand over the forecast period as these therapies specifically target tumor cells carrying specific mutations which may not respond well with standard chemotherapeutic drugs or radiation therapy.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players, high awareness levels about early diagnosis, and availability of effective treatment methods are some factors driving the regional market. In addition, supportive government initiatives for cancer research and development as well as increasing healthcare expenditure by governments are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels in emerging countries such as China and India coupled with growing patient awareness regarding HER2-positive breast cancer treatments along with their benefits & efficacy. Moreover, an increase in biotechnology companies focusing on drug discovery activities is also expected to boost revenue generation during the estimated time span (2018-2030).
Growth Factors:
- Increasing incidence of breast cancer: The incidence of breast cancer is increasing at a rapid pace across the globe. This is mainly attributed to the changing lifestyle and dietary habits, growing population, and aging population. HER2-positive breast cancer accounts for around 20%–25% of all diagnosed cases of breast cancer. Thus, the increasing incidence of breast cancer is expected to drive the growth of HER2-positive Breast Cancer market in the coming years.
- Growing awareness about early detection and treatment options: There is a growing awareness among people about early detection and treatment options for various types of cancers including HER2-positive Breast Cancer. This has led to an increase in demand for diagnostic tests and therapies for HER2-positive Breast Cancer patients worldwide.
- Technological advancements in diagnostics and therapeutics: The technological advancements in diagnostics and therapeutics are aiding in better diagnosis and treatment outcomes for patients with HER2-positive Breast Cancer tumors respectively. This is resulting in increased adoption rates of diagnostic tests/therapies among healthcare professionals as well as patients globally thereby propelling the growth prospects of this market during forecast period 2017–2025 .
Scope Of The Report
Report Attributes
Report Details
Report Title
HER2-Positive Breast Cancer Market Research Report
By Type
Grifola Frondosa, Surgery, Radiation and Chemotherapy, Endocrine Therapy, Molecular Targeted Therapy, HER2-Positive Breast Cance
By Application
Hospital, Specialist Clinic, Biotechnology and Pharmaceutical Companies, Research and Academic Institutions, Other
By Companies
Pfizer (Pharmacia and Upjohn Company), Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Roche Group, Merck, Jiangsu HengRui Medicine, Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Syndax Pharmaceuticals, Bayer, Eagle Pharmaceuticals, Merrimack Pharmaceuticals, GlaxoSmithKline, Millennium Pharmaceuticals, HER2-Positive Breast Cance
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global HER2-Positive Breast Cancer Market Report Segments:
The global HER2-Positive Breast Cancer market is segmented on the basis of:
Types
Grifola Frondosa, Surgery, Radiation and Chemotherapy, Endocrine Therapy, Molecular Targeted Therapy, HER2-Positive Breast Cance
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Specialist Clinic, Biotechnology and Pharmaceutical Companies, Research and Academic Institutions, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer (Pharmacia and Upjohn Company)
- Novartis
- AstraZeneca Pharmaceuticals
- Eli Lilly
- Roche Group
- Merck
- Jiangsu HengRui Medicine
- Odonate Therapeutics
- Radius Pharmaceuticals
- Immunomedics
- Syndax Pharmaceuticals
- Bayer
- Eagle Pharmaceuticals
- Merrimack Pharmaceuticals
- GlaxoSmithKline
- Millennium Pharmaceuticals
- HER2-Positive Breast Cance
Highlights of The HER2-Positive Breast Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Grifola Frondosa
- Surgery
- Radiation and Chemotherapy
- Endocrine Therapy
- Molecular Targeted Therapy
- HER2-Positive Breast Cance
- By Application:
- Hospital
- Specialist Clinic
- Biotechnology and Pharmaceutical Companies
- Research and Academic Institutions
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the HER2-Positive Breast Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
HER2-positive breast cancer is a type of cancer that has increased levels of the HER2 protein. This protein helps to control the growth and spread of other types of cancers. When HER2-positive breast cancer is treated with surgery, radiation therapy, and/or chemotherapy, it can often be cured. However, if the tumor grows back or spreads to other parts of the body (metastasizes), then treatment may be needed again.
Some of the major players in the her2-positive breast cancer market are Pfizer (Pharmacia and Upjohn Company), Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Roche Group, Merck, Jiangsu HengRui Medicine, Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Syndax Pharmaceuticals, Bayer, Eagle Pharmaceuticals, Merrimack Pharmaceuticals, GlaxoSmithKline, Millennium Pharmaceuticals, HER2-Positive Breast Cance.
The her2-positive breast cancer market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. HER2-Positive Breast Cancer Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. HER2-Positive Breast Cancer Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. HER2-Positive Breast Cancer Market - Supply Chain
4.5. Global HER2-Positive Breast Cancer Market Forecast
4.5.1. HER2-Positive Breast Cancer Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. HER2-Positive Breast Cancer Market Size (000 Units) and Y-o-Y Growth
4.5.3. HER2-Positive Breast Cancer Market Absolute $ Opportunity
5. Global HER2-Positive Breast Cancer Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. HER2-Positive Breast Cancer Market Size and Volume Forecast by Type
5.3.1. Grifola Frondosa
5.3.2. Surgery
5.3.3. Radiation and Chemotherapy
5.3.4. Endocrine Therapy
5.3.5. Molecular Targeted Therapy
5.3.6. HER2-Positive Breast Cance
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global HER2-Positive Breast Cancer Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. HER2-Positive Breast Cancer Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Specialist Clinic
6.3.3. Biotechnology and Pharmaceutical Companies
6.3.4. Research and Academic Institutions
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global HER2-Positive Breast Cancer Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. HER2-Positive Breast Cancer Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global HER2-Positive Breast Cancer Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. HER2-Positive Breast Cancer Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global HER2-Positive Breast Cancer Demand Share Forecast, 2019-2026
9. North America HER2-Positive Breast Cancer Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America HER2-Positive Breast Cancer Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America HER2-Positive Breast Cancer Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Specialist Clinic
9.4.3. Biotechnology and Pharmaceutical Companies
9.4.4. Research and Academic Institutions
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America HER2-Positive Breast Cancer Market Size and Volume Forecast by Type
9.7.1. Grifola Frondosa
9.7.2. Surgery
9.7.3. Radiation and Chemotherapy
9.7.4. Endocrine Therapy
9.7.5. Molecular Targeted Therapy
9.7.6. HER2-Positive Breast Cance
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America HER2-Positive Breast Cancer Demand Share Forecast, 2019-2026
10. Latin America HER2-Positive Breast Cancer Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America HER2-Positive Breast Cancer Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America HER2-Positive Breast Cancer Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Specialist Clinic
10.4.3. Biotechnology and Pharmaceutical Companies
10.4.4. Research and Academic Institutions
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America HER2-Positive Breast Cancer Market Size and Volume Forecast by Type
10.7.1. Grifola Frondosa
10.7.2. Surgery
10.7.3. Radiation and Chemotherapy
10.7.4. Endocrine Therapy
10.7.5. Molecular Targeted Therapy
10.7.6. HER2-Positive Breast Cance
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America HER2-Positive Breast Cancer Demand Share Forecast, 2019-2026
11. Europe HER2-Positive Breast Cancer Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe HER2-Positive Breast Cancer Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe HER2-Positive Breast Cancer Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Specialist Clinic
11.4.3. Biotechnology and Pharmaceutical Companies
11.4.4. Research and Academic Institutions
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe HER2-Positive Breast Cancer Market Size and Volume Forecast by Type
11.7.1. Grifola Frondosa
11.7.2. Surgery
11.7.3. Radiaion and Chemotherapy
11.7.4. Endocrine Therapy
11.7.5. Molecular Targeted Therapy
11.7.6. HER2-Positive Breast Cance
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe HER2-Positive Breast Cancer Demand Share, 2019-2026
12. Asia Pacific HER2-Positive Breast Cancer Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific HER2-Positive Breast Cancer Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific HER2-Positive Breast Cancer Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Specialist Clinic
12.4.3. Biotechnology and Pharmaceutical Companies
12.4.4. Research and Academic Institutions
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific HER2-Positive Breast Cancer Market Size and Volume Forecast by Type
12.7.1. Grifola Frondosa
12.7.2. Surgery
12.7.3. Radiation and Chemotherapy
12.7.4. Endocrine Therapy
12.7.5. Molecular Targeted Therapy
12.7.6. HER2-Positive Breast Cance
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific HER2-Positive Breast Cancer Demand Share, 2019-2026
13. Middle East & Africa HER2-Positive Breast Cancer Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa HER2-Positive Breast Cancer Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa HER2-Positive Breast Cancer Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Specialist Clinic
13.4.3. Biotechnology and Pharmaceutical Companies
13.4.4. Research and Academic Institutions
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa HER2-Positive Breast Cancer Market Size and Volume Forecast by Type
13.7.1. Grifola Frondosa
13.7.2. Surgery
13.7.3. Radiation and Chemotherapy
13.7.4. Endocrine Therapy
13.7.5. Molecular Targeted Therapy
13.7.6. HER2-Positive Breast Cance
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa HER2-Positive Breast Cancer Demand Share, 2019-2026
14. Competition Landscape
14.1. Global HER2-Positive Breast Cancer Market: Market Share Analysis
14.2. HER2-Positive Breast Cancer Distributors and Customers
14.3. HER2-Positive Breast Cancer Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer (Pharmacia and Upjohn Company)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AstraZeneca Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eli Lilly
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Roche Group
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Jiangsu HengRui Medicine
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Odonate Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Radius Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Immunomedics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Syndax Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Bayer
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Eagle Pharmaceuticals
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Merrimack Pharmaceuticals
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. GlaxoSmithKline
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Millennium Pharmaceuticals
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. HER2-Positive Breast Cance
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Fina
